Arcus Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 3 Sell calls were followed by a 20% average decline over the next quarter.
- Recent price momentum is -36.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 9.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -156.3% | Better than 6% |
| Net margin | -142.9% | Better than 6% |
| Return on equity | -63.3% | Better than 8% |
| Return on invested capital | -59.9% | Better than 5% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -48.5% | Better than 6% |
| 6-month return | -33.3% | Better than 16% |
| 12-month return (ex latest month) | -15.9% | Better than 18% |
| Distance below 52-week high | 50.8% | Better than 18% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.4x | Better than 83% |
| Debt to assets | 9.8% | Better than 70% |
| Interest coverage | -43.1x | Better than 8% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 166.6% | Better than 92% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 15.78
- Open
- 15.66
- Day range
- 15.56 - 16.66
- Avg price
- 15.80
- Volume
- 1.67M
- Turnover
- 26.45M
- Turnover ratei
- 1.56%
- Volume ratioi
- 1.16
- Amplitudei
- 6.97%
- 52-week rangei
- 15.56 - 31.74
Valuation
- P/Ei
- -4.75
- P/E (TTM)i
- -4.29
- P/Bi
- 6.28
- EPSi
- -3.29
- Book value / shi
- 2.49
- Net profit
- -473.73M
- Net assets
- 357.96M
Share structure
- Market cap
- 2.25B
- Float capi
- 1.67B
- Shares out
- 143.99M
- Float sharesi
- 107.19M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-03-15
50.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.95M net over the window
Short interest
- Shares short
- 13.18M
- % of floati
- 9.31%
- Days to coveri
- 3.56
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Arcus Biosciences (RCUS)?
Arcus Biosciences last traded at 15.62. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Arcus Biosciences's market cap?
About 2.25B.
What is the P/E ratio of Arcus Biosciences?
The trailing twelve-month P/E is -4.29, below its own 5-year average of 1.59 — in the middle of its historical range (46.25% percentile). See the Valuation tab for the full history.
Does Arcus Biosciences pay a dividend?
Arcus Biosciences does not currently pay a regular dividend.
Is Arcus Biosciences a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 41.64, which implies 166.6% upside from the current price. This is not investment advice.
What is Arcus Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Arcus Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.
Arcus Biosciences discussion 0 comments